Recent mumps outbreaks in vaccinated populations: No evidence of immune escape

Journal of Virology

Volumn 86, Issue 1, 2012, Pages 615-620

  Rubin, Steven A ^a   Link, Malen A ^a,d   Sauder, Christian J ^a   Zhang, Cheryl ^a   Ngo, Laurie ^a   Rima, Bert K ^b   Paul Duprex, W ^c  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SCHAFER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; NEUTRALIZING ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; EPIDEMIC; GENE FUNCTION; GENETIC VARIABILITY; HUMAN; MUMPS; PRIORITY JOURNAL; VACCINE FAILURE; VIRUS GENE; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT; VIRUS STRAIN;

MUMPS VIRUS; RUBELLA;

EID: 84862973543     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06125-11     Document Type: Article

References (64)

1. Afzal MA, Buchanan J, Heath AB, Minor PD. 1997. Clustering of mumps virus isolates by SH gene sequence only partially reflects geographic origin. Arch. Virol. 142:227-238.
2. Afzal MA, Pickford AR, Forsey T, Heath AB, Minor PD. 1993. The Jeryl Lynn vaccine strain of mumps virus is a mixture of two distinct isolates. J. Gen. Virol. 74:917-920.
3. Akcali A, Yilmaz N, Uyar Y, Ertek M, Buzgan T. 2009. Genotyping of mumps virus circulating in Turkey in the 2006-2007 winter season. Arch. Virol. 154:1807-1812.
4. Amexis G, Rubin S, Chatterjee N, Carbone K, Chumakov K. 2003. Identification of a new genotype H wild-type mumps virus strain and its molecular relatedness to other virulent and attenuated strains. J. Med. Virol. 70:284 -286.
5. Bangor-Jones RD, et al. 2009. A prolonged mumps outbreak among highly vaccinated Aboriginal people in the Kimberley region of Western Australia. Med. J. Aust. 191:398-401.
6. Barskey AE, Glasser JW, LeBaron CW. 2009. Mumps resurgences in the United States: a historical perspective on unexpected elements. Vaccine 27:6186-6195.
7. Boxall N, Kubinyiova M, Prikazsky V, Benes C, Castkova J. 2008. An increase in the number of mumps cases in the Czech Republic, 2005-2006. Euro Surveill. 13:pii:18842.
8. Brunell PA, Brickman A, Steinberg S. 1969. Evaluation of a live attenuated mumps vaccine (Jeryl Lynn). With observations on the optimal time for testing serologic response. Am. J. Dis. Child. 118:435-440.
9. Carbone KM, Rubin S. 2007. Mumps virus, p 1527-1542. In Knipe DM, et al (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
10. Castilla J, et al. 2009. Effectiveness of Jeryl Lynn-containing vaccine in Spanish children. Vaccine 27:2089 -2093.
11. Centers for Disease Control and Prevention. 1986. Mumps-United States, 1984-1985. Morb. Mortal. Wkly. Rep. 35:216 -219.
12. Centers for Disease Control and Prevention. 1994. Summary of notifiable diseases, United States, 1993. Morb. Mortal. Wkly. Rep. 42:i-xvii, 1-73.
13. Centers for Disease Control and Prevention. 2006. Brief report: update: mumps activity-United States, January 1-October 7, 2006. Morb. Mortal. Wkly. Rep. 55:1152-1153.
14. Centers for Disease Control and Prevention. 2010. Update: mumps outbreak-New York and New Jersey, June 2009-January 2010. Morb. Mortal. Wkly. Rep. 59:125-129.
15. Chamot E, Toscani L, Egger P, Germann D, Bourquin C. 1998. Estimation of the efficacy of three strains of mumps vaccines during an epidemic of mumps in the Geneva canton (Switzerland). Rev. Epidemiol. Sante Publique 46:100 -107. (In French.)
16. Chen M, et al. 2009. Comparison of genotype characteristics between the circulating mumps virus strain in Beijing area and the vaccine strain. Zhonghua Liu Xing Bing Xue Za Zhi 30:1184 -1188. (In Chinese.)
17. Cohen C, et al. 2007. Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England. Emerg. Infect. Dis. 13:12-17.
18. Cooney MK, Fox JP, Hall CE. 1975. The Seattle Virus Watch. VI. Observations of infections with and illness due to parainfluenza, mumps and respiratory syncytial viruses and Mycoplasma pneumoniae. Am. J. Epidemiol. 101:532-551.
19. Cortese MM, et al. 2008. Mumps vaccine performance among university students during a mumps outbreak. Clin. Infect. Dis. 46:1172-1180.
20. Crowley B, Afzal MA. 2002. Mumps virus reinfection-clinical findings and serological vagaries. Commun. Dis. Public Health 5:311-313.
21. Cusi MG, et al. 2001. Localization of a new neutralizing epitope on the mumps virus hemagglutinin-neuraminidase protein. Virus Res. 74: 133-137.
22. Cusi MG, Valensin PE, Donati M, Valassina M. 2001. Neutralization of Toscana virus is partially mediated by antibodies to the nucleocapsid protein. J. Med. Virol. 63:72-75.
23. Reference deleted.
24. Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. 2008. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J. Infect. Dis. 197:950 -956.
25. Davidkin I, Valle M, Julkunen I. 1995. Persistence of anti-mumps virus antibodies after a two-doseMMRvaccination: a nine-year follow-up. Vaccine 13:1617-1622.
26. Davis JP, Akella S, Waddell PH. 2004. Accelerating phylogenetics computing on the desktop: experiments with executing UPGMA in programmable logic. Conf. Proc. IEEE Eng. Med. Biol. Soc. 4:2864 -2868.
27. Dayan GH, Rubin S. 2008. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks? Clin. Infect. Dis. 47:1458 -1467.
28. Elango N, Varsanyi TM, Kovamees J, Norrby E. 1988. Molecular cloning and characterization of six genes, determination of gene order and intergenic sequences and leader sequence of mumps virus. J. Gen. Virol. 69: 2893-2900.
29. Elliott GD, et al. 1990. Strain-variable editing during transcription of the P gene of mumps virus may lead to the generation of non-structural proteins NS1 (V) and NS2. J. Gen. Virol. 71:1555-1560.
30. Enders JF, Levens JH. 1946. Attenuation of virulence with retention of antigenicity of mumps virus after passage in the embryonated egg. J. Immunol. 54:283-291.
31. Fu C, Liang J, Wang M. 2008. Matched case-control study of effectiveness of live, attenuated S79 mumps virus vaccine against clinical mumps. Clin. Vaccine Immunol. 15:1425-1428.
32. Galazka AM, Robertson SE, Kraigher A. 1999. Mumps and mumps vaccine: a global review. Bull. World Health Organ. 77:3-14.
33. Hindiyeh MY, et al. 2009. Characterization of large mumps outbreak among vaccinated Palestinian refugees. J. Clin. Microbiol. 47:560 -565.
34. Houard S, Varsanyi TM, Milican F, Norrby E, Bollen A. 1995. Protection of hamsters against experimental mumps virus (MuV) infection by antibodies raised against the MuV surface glycoproteins expressed from recombinant vaccinia virus vectors. J. Gen. Virol. 76:421- 423.
35. Kovamees J, Rydbeck R, Orvell C, Norrby E. 1990. Hemagglutininneuraminidase (HN) amino acid alterations in neutralization escape mutants of Kilham mumps virus. Virus Res. 17:119 -129.
36. Kumar S, Tamura K, Nei M. 2004. MEGA3: integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief. Bioinform. 5:150-163.
37. Lamb RA, Parks GD. 2007. Paramyxoviridae: the viruses and their replication, p 1449-1496. In Knipe DM, et al (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
38. LeBaron CW, et al. 2009. Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine. J. Infect. Dis. 199:552-560.
39. Lecomte J, et al. 1987. Protection from mouse hepatitis virus type 3-induced acute disease by an anti-nucleoprotein monoclonal antibody. Arch. Virol. 97:123-130.
40. Liang Y, et al. 2008. Immunogenicity and safety of a novel formalininactivated and alum-adjuvanted candidate subunit vaccine for mumps. Vaccine 26:4276-4283.
41. Lodmell DL, Esposito JJ, Ewalt LC. 1993. Rabies virus antinucleoprotein antibody protects against rabies virus challenge in vivo and inhibits rabies virus replication in vitro. J. Virol. 67:6080-6086.
42. Marin M, et al. 2008. Mumps vaccination coverage and vaccine effectiveness in a large outbreak among college students-Iowa, 2006. Vaccine 26:3601-3607.
43. McNabb SJ, et al. 2007. Summary of notifiable diseases-United States, 2005. MMWR Morb. Mortal. Wkly. Rep. 54:1-92.
44. Mortimer PP. 1978. Mumps prophylaxis in the light of a new test for antibody. Br. Med. J. 2:1523-1524.
45. Nojd J, Tecle T, Samuelsson A, Orvell C. 2001. Mumps virus neutralizing antibodies do not protect against reinfection with a heterologous mumps virus genotype. Vaccine 19:1727-1731.
46. Ong G, Goh KT, Ma S, Chew SK. 2005. Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. J. Infect. 51:294 -298.
47. Orvell C. 1984. The reactions of monoclonal antibodies with structural proteins of mumps virus. J. Immunol. 132:2622-2629.
48. Orvell C, Alsheikhly AR, Kalantari M, Johansson B. 1997. Characterization of genotype-specific epitopes of theHNprotein of mumps virus. J. Gen.Virol. 78:3187-3193.
49. Park DW, et al. 2007. Mumps outbreak in a highly vaccinated school population: assessment of secondary vaccine failure using IgG avidity measurements. Vaccine 25:4665- 4670.
50. Peltola H, et al. 2000. Mumps and rubella eliminated from Finland. JAMA 284:2643-2647.
51. Plotkin SA, Rubin SA. 2008. Mumps vaccine, p 435-465. InPlotkin SA, Orenstein WA, and Offit PA (ed), Vaccines, 5th ed. Saunders Elsevier, Philadelphia, PA.
52. Roberts C, Porter-Jones G, Crocker J, Hart J. 2009. Mumps outbreak on the island of Anglesey, North Wales, December 2008-January 2009. Euro Surveill. 14:pii:19109.
53. Rota JS, et al. 2009. Investigation of a mumps outbreak among university students with two measles-mumps-rubella (MMR) vaccinations, Virginia, September-December 2006. J. Med. Virol. 81:1819 -1825.
54. Rubin SA, et al. 2008. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wildtype mumps virus associated with a large outbreak. J. Infect. Dis. 198: 508-515.
55. Saito H, et al. 1998. Cloning and characterization of the genomic RNA sequence of the mumps virus strain assoicated with a high incidence of aseptic meningitis. Microbiol. Immunol. 42:133-137.
56. Sauder CJ, et al. 2011. Gene-specific contributions to mumps virus neurovirulence and neuroattenuation. J. Virol. 85:7059 -7069.
57. Schwarz NG, et al. 2010. Mumps outbreak in the Republic of Moldova, 2007-2008. Pediatr. Infect. Dis. J. 29:703-706.
58. Slater PE, Anis E, Leventhal A. 1999. The control of mumps in Israel. Eur. J. Epidemiol. 15:765-767.
59. Somboonthum P, et al. 2007. Generation of a recombinant Oka varicella vaccine expressing mumps virus hemagglutinin-neuraminidase protein as a polyvalent live vaccine. Vaccine 25:8741- 8755.
60. Tecle T, Johansson B, Yun Z, Orvell C. 2000. Antigenic and genetic characterization of the fusion (F) protein of mumps virus strains. Arch. Virol. 145:1199 -1210.
61. Vandermeulen C, et al. 2004. Outbreak of mumps in a vaccinated child population: a question of vaccine failure? Vaccine 22:2713-2716.
62. Watson-Creed G, et al. 2006. Two successive outbreaks of mumps in Nova Scotia among vaccinated adolescents and young adults. CMAJ. 175:483-488.
63. Wolinsky JS, Waxham MN, Server AC. 1985. Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitis. J. Virol. 53:727-734.
64. Yamanishi K, Takahashi M, Ueda S, Minekawa Y, Ogino T. 1973. Studies on live mumps virus vaccine. V. Development of a new mumps vaccine "AM 9" by plaque cloning. Biken J. 16:161-166.